




TASHKENT MEDICAL ACADEMY

100 TMA
ANNIVERSARY



Journal of Educational and Scientific Medicine



Issue 3 (2) | 2023



OAK.UZ
Google Scholar

Science Education Commission of the Cabinet
Ministry of the Republic of Uzbekistan

ISSN: 2181-3175

A Review on Glimpiride vs Teneligliptin as a Second-Line Drug for the Treatment of Type 2 Diabetes Mellitus

A. Saara, K. Gopal, S. Karthick, A. Ashi, K. Karthickeyan¹

ABSTRACT

Type 2 diabetes mellitus (T2DM) is a condition caused by reduced insulin sensitivity. Those above the age of 45 have an increased risk of developing type 2 diabetes. Oral hypo-glycaemic agents are used to treat type 2 diabetes. Metformin is usually the initial therapy and if it is still insufficient, a second oral medication of a different class will be added. Whereas sulfonylureas and dipeptidyl peptidase-4 inhibitors are the most used second-line drug categories for type 2 diabetes mellitus. Sulfonylureas are used to control hyperglycemia and the glycated haemoglobin A1C (HbA1c) levels can be lowered by 1% to 1.25% when using sulfonylurea, making them just as effective as other options. Mainly glimepiride remains the most widely used sulfonylurea in type 2 diabetes mellitus. Glimpiride enhances glycemic control although glimepiride stimulates endogenous insulin secretion, causing hypoglycemia also causes weight gain, which might complicate diabetes therapy. DPP-4 is a widely distributed enzyme that regulates incretin hormones, which regulate glucose homeostasis by boosting insulin production and lowering glucagon secretion. When compared to other DPP-4 inhibitors, teneligliptin has a unique J-shaped or anchor-locked domain structure because of which it has a potent inhibitory effect on the DPP-4 enzyme and has a low IC₅₀, high potency, and fewer side effects. It is the only DPP-4 inhibitor with a prolonged half-life. Teneligliptin was found to improve blood glucose levels over a period of 24 hours such as reducing the postprandial insulin requirement and reducing glucagon secretion. Thus, compared to glimepiride, teneligliptin is a better choice as a second-line drug for type 2 diabetes mellitus after metformin usage, irrespective of the patient's age and gender.

Keywords: Type 2 diabetes mellitus, sulfonylurea, dipeptidyl peptidase-4 inhibitors, glimepiride, teneligliptin

INTRODUCTION

Around 90% of all instances of diabetes are due to type 2 diabetes mellitus (T2DM). Reduced insulin sensitivity characterizes type 2 diabetes, a condition known as insulin resistance. Initially, an increase in insulin production is mounted to compensate for insulin resistance and keep glucose homeostasis stable, but this response eventually wears off, leaving the body vulnerable to the development of type 2 diabetes. Those above the age of 45 have an increased risk of developing type 2 diabetes. Yet, owing to increased rates of obesity, inactivity, and energy-dense meals, its prevalence among children, adoles-

cents, and young adults is on the rise [1]. Common symptoms of diabetes mellitus include excessive thirst and urination, extreme weariness and weakness, susceptibility to infections from bacteria and fungi, and impaired wound healing. Patients may also experience blurred vision, numbness, or tingling. Haemoglobin A1C or plasma glucose will be used to diagnose diabetes. Oral hypo-glycaemic agents are used to treat type 2 diabetes. Metformin is usually the initial therapy since it may reduce mortality [2,3,4]. If, after three months, metformin is still insufficient, a second oral medication of a different class will be added. Sulfonylureas, thiazolidine-

¹ Corresponding Authors: Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Sciences, Technology and Advanced Studies, Pallavaram, Chennai-600117, Tamil Nadu, India.

diones, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) analogues are further groups of drugs used to treat diabetes[5]. Whereas sulfonylureas and dipeptidyl peptidase-4 inhibitors are the most used second-line drug categories for type 2 diabetes mellitus. Thus, this review gets further narrowed down to a particular drug from each drug class, such as glimepiride (sulfonylurea) versus teneligliptin (dipeptidyl peptidase-4 inhibitors) as the best second-line drug for the treatment of type 2 diabetes mellitus.

Sulfonylurea

The first and foremost discovered sulfonylurea is carbutamide in 1942, as it has high side effects it has failed to use. During the 1960s several sulfonylureas were discovered as first generation and later with second generation. In consideration, second generations are widely used now. Both the generations have same efficacy and safety [6].

Sulfonylureas stimulates pancreatic beta cells to secrete insulin and reduces its hepatic clearance by blocking the inflow of potassium (K⁺) through the ATP-dependent channel: the flow of K⁺ within the β -cell goes to zero, the cell membrane becomes depolarized, thus removing the electric screen which prevents the diffusion of calcium into the cytosol. The increased flow of calcium into β -cells causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin, which is therefore promptly secreted in large amounts [6].

Sulfonylureas have a high rate of absorption. The absorption of glipizide is slowed down by meals. Ninety to ninety-nine per cent of sulfonylureas are linked to proteins in the plasma. Chlorpropamide has the lowest affinity for plasma proteins, whereas glyburide has the highest affinity. The liver is responsible for metabolising sulfonylureas, and the metabolites are then eliminated in the urine. There is a significant amount of variety among first-generation sulfonylureas regarding both their half-lives and the degree of their metabolism. Chlorpropamide has an inefficient metabolic pathway, which results in roughly 20% of the medication being excreted intact. This presents a challenge for individuals whose renal function is already compromised [7].

Based on their effectiveness in controlling diabetes, sulfonylureas are categorised into three groups: Acetohexamide, carbutamide, chlorpropamide, glycyclamide (tolcyclamide), metahexamide, tolazamide, and tolbutamide are a few examples of first-generation medica-

tions. A few of these are glibenclamide, glyburide, glibornuride, gliclazide [8], glipizide, gliquidone, glisoxepide, and glycopyramide. Glimepiride is a third-generation medication, although occasionally categorised as a second-generation drug [9,10].

Sulfonylureas are used to control hyperglycemia in type 2 diabetics who cannot achieve appropriate control with changes in diet and exercise alone [7]. The glycated haemoglobin A1C (HbA1c) levels can be lowered by 1% to 1.25% when using sulfonylurea, making them just as effective as other options [11]. Despite better glycemic control in the short term, diabetes could worsen in the long term as sulfonylureas act directly on beta cells which may lead to the destruction of beta cells of the pancreas. The clinical result of this phenomenon is known as “secondary failure” [12].

Despite the large number of anti-diabetic agents available, however, sulfonylureas mainly glimepiride remains the most widely used drug for treating patients with type 2 diabetes [13].

Glimepiride

Glimepiride is a part of the pharmacological family known as second-generation sulfonylurea (SU), which was first made available in 1995. It is prescribed for the treatment of type 2 diabetes mellitus (T2DM), which aims to enhance glycemic control [6] and is also used as a second-line medication in combination therapy with metformin.

Like other sulfonylureas, glimepiride is an insulin secretagogue that works best in those who still have some functioning beta cells in their pancreas. Iatrogenic depolarization is induced by their blocking of potassium efflux via ATP-dependent potassium channels on the cell membrane of pancreatic beta cells. Increased intracellular calcium triggers insulin exocytosis into the circulation, and membrane voltage-dependent calcium channels are activated by depolarization [14]. The action of insulin on cell membrane receptors results in the production of GLUT-4 and the uptake of glucose into the cell, hence reducing glucose levels in the blood. In addition, studies have demonstrated that glimepiride interacts with Epac3, a nucleotide exchanger that plays a role in mediating the exocytosis of insulin granules [15,16,17].

Glimepiride has a pharmacokinetics profile that is linear, which means that it is entirely absorbed after oral administration within one hour of administration [18]. The amount of glimepiride that is bound to proteins in plasma is more than 99.5% [19]. It has been stated that glimepiride is subject to hepatic metabolism. Whether

glimepiride is administered intravenously or orally, the drug goes through oxidative biotransformation that is mediated by the CYP2C9 enzyme. This biotransformation results in the formation of a major metabolite called cyclohexyl hydroxymethyl derivative (M1), which is pharmacologically active. One or more of the cytosolic enzymes may convert M1 into the inactive metabolite carboxyl derivative (M2) as the next step in the metabolic pathway. In an animal model, M1 maintained roughly one-third of the pharmacologic activity of its parent, and its half-life ranged from three to six hours [6]. It is not obvious, however, whether the glucose-lowering impact of M1 is important on a clinical level. Around 65% of it is eliminated in the urine, while the remaining 35% is eliminated in the faeces [19].

Glimepiride's effect lasts far longer than that of glipizide, which is also a second-generation sulfonylurea medication. Because it has a greater number of substitutions than other SUs of the second generation, it is frequently referred to as a third-generation sulfonylurea. It has been shown to be successful in lowering levels of glycosylated haemoglobin, fasting plasma glucose, and postprandial glucose and is regarded as a beneficial and cost-effective therapy choice for the management of type 2 diabetes mellitus [18].

Although glimepiride stimulates endogenous insulin secretion, causing hypoglycemia. Hypoglycemic unawareness may cause neuroglycopenia and hypoglycemic coma in long-term diabetics. If additional hypoglycemic agents are used, drivers and skilled workers are at risk. Sulfonylureas like glimepiride can cause weight gain, which might complicate diabetes therapy as weight reduction is a goal. Additional potentially dangerous side effects include nausea, vomiting, stomach discomfort, diarrhoea, Stevens-Johnson syndrome, and erythroderma [6,18]. Nevertheless, in comparison to the incidences of adverse effects related to other sulfonylureas, those connected with glimepiride are typically lower [18].

Dipeptidyl peptidase-4 inhibitor (Dpp- 4 inhibitor)

DPP-4 inhibitors are generally effective at inhibiting DPP-4, and under clinical circumstances, DPP-4 is inhibited by >80-90%. This inhibition causes a 2-3-fold increase in post-prandial GLP-1 plasma concentrations, which mediates the glucose-dependent stimulation of insulin secretion and suppression of glucagon secretion [20,21]. Apart from this "endocrine" impact, DPP-4 inhibitors' local inhibitory effect on GLP-1 breakdown in the intestinal mucosa may help to beneficial metabolic control by activating the autonomic afferent neural sys-

tem [20,21]. DPP-4 inhibitors can reduce the HbA1c percentage by 0.5-1 unit. The decrease in HbA1c, like with other antihyperglycemic medicines, is mostly determined by the patient group observed, the baseline glycemic status at the start of the observation, and the concomitant therapy, including lifestyle modification [21,22,23,24].

DPP-4 is a widely distributed enzyme that regulates incretin hormones, primarily GIP (gastric inhibitory peptide and GLP-1 (glucagon-like peptide-1), which regulate glucose homeostasis by boosting insulin production and lowering glucagon secretion [25]. GLP-1 is a hormone released by enteroendocrine L cells which is present in the small intestine that decreases blood glucose by boosting insulin production, decreasing glucagon concentrations, and prolonging stomach emptying [26].

A study of sitagliptin oral and IV delivery in healthy volunteers found that the oral dosage was approximately 87% bioavailable. When compared to fasting levels, eating a high-fat meal had no effect on the agent's bioavailability, maximum plasma concentration (C_{max}), or half-life [27]. Studies comparing fed and fasted states in plasma area-under-the-curve (AUC) concentrations of sitagliptin and saxagliptin found a 20% and 27% elevation when the medications were taken with a meal, respectively [28,29]. The distribution of sitagliptin and saxagliptin is usually influenced by several variables, including plasma protein binding. These medicines have a modest affinity for serum proteins. Illness conditions that modify protein levels are therefore unlikely to cause large differences in the disposition of these drugs [28,30]. Metabolism is predominantly handled by the cytochrome P450 (CYP 450) 3A4/5 pathway, as a result, inhibitors and inducers of this pathway are predicted to alter the drug concentrations [28]. Oral dosages of DPP4 inhibitors are eliminated via renal and hepatic routes. Sitagliptin has a terminal half-life of roughly 12.4 hours, compared to saxagliptin with a half-life life of 2.5 hours and metabolite has 3.1 hours [28,30].

When compared to other DPP-4 inhibitors, teneligliptin has a unique J-shaped or anchor-locked domain structure because of which it has a potent inhibitory effect on the DPP-4 enzyme [31] and has a low IC₅₀, high potency, and fewer side effects. It is the only DPP-4 inhibitor with a prolonged half-life [32].

Teneligliptin

Teneligliptin is an inhibitor of dipeptidyl peptidase-4 that belongs to the third generation and was first created by Mitsubishi Tanabe Pharma Company [33], which was authorised for the treatment of T2DM in Japan in Sep-

tember 2012 [34]. It is presently accessible in Japan, India, Argentina, and South Korea [35].

Teneligliptin has a very rigid "J-shaped" structure, which is formed by five rings. Four of these rings are directly attached to DPP-4, which results in the highest binding to DPP-4 enzymes when compared to other gliptins [35]. Since plasma DPP-4 activity dropped by a large amount after switching to teneligliptin, it is possible that teneligliptin is a stronger DPP-4 inhibitor than other drugs. Teneligliptin binds to the DPP-4 enzyme's S1, S2, and S2 extensive subsites. This makes the drug more effective and selective. In addition, when teneligliptin is bound to the S2 extensive site in addition to the S1 and S2 sites, a more potent inhibitory effect is bestowed upon the DPP-4 enzyme. Furthermore, teneligliptin was shown to have the J-shaped anchor-lock domain, strong covalent connections with DPP-4, and more widespread S2 extensive binding, all of which demonstrated that it has a stronger inhibitory action [34,36,37].

A meal triggers the release of glucagon-like peptide-1 (GLP-1) from the alimentary canal, which encourages pancreatic insulin production and controls glucagon secretion to manage blood sugar levels after meals. By decreasing the activity of dipeptidyl peptidase-4 (DPP-4) and thus raising the blood levels of active GLP-1, teneligliptin has a hypoglycemic effect by preventing GLP-1 from being degraded [38].

Teneligliptin has a quick absorption rate in healthy volunteers following a single 20 mg dosage, with maximal plasma concentrations being reached in 1.33 hours. Between 78% and 80% of the medication is bound to the proteins in the plasma [35]. Teneligliptin is largely metabolised in humans by cytochrome P450 (CYP) 3A4 and flavin monooxygenases (FMO) 1 and 3, which results in the production of several metabolites with unclear biological activity [35,39]. After a single dosage of 20 mg radiolabelled teneligliptin, the most abundant metabolite is a thiazolidine-1-oxide derivative that has been classified as M1. This thiazolidine-1-oxide derivative accounts for 14.7% of the AUC total radioactivity [40]. At least 90 per cent of the dosage was eliminated from the body after 216 hours, with 45.4% of it being eliminated via the urine and 46.6% through the faeces [41].

Teneligliptin is indicated for managing type 2 diabetes mellitus along with diet and exercise [37]. Teneligliptin was found to improve blood glucose levels over a period of 24 hours by increasing active incretin levels and early-phase insulin secretion, reducing the postprandial insulin requirement, and reducing glucagon

secretion. The researchers who conducted the study concluded that even short-term treatment with teneligliptin may offer benefits to patients who suffer from type 2 diabetes. Most notably, there is no need to change the dosage of teneligliptin for patients with type 2 diabetes (T2D) who have renal impairment or even end-stage renal disease since it is efficacious and well tolerated by these people [42]. Thus, Teneligliptin was regarded as well-tolerated and manageable in Type 2 diabetes mellitus [37].

Another study has reported that the postprandial blood glucose-lowering effects of teneligliptin administered prior to breakfast were sustained throughout the day, and the effects observed after dinner were like those observed after breakfast or lunch. Thus, although clinical data for this new drug are limited, this drug shows promise in stabilizing glycemic fluctuations throughout the day and consequently suppressing the progression of diabetic complications [34].

The usage of teneligliptin was not linked to an elevated risk of cardiovascular events, including all-cause mortality, heart failure, or atherothrombotic events. In addition, when compared to sulfonylureas, teneligliptin was shown to be related to a reduced likelihood of hypoglycemia [43].

CONCLUSION

The most prevalent endocrine illness and a major contributor to death and morbidity is type 2 diabetes mellitus. To effectively treat patients with type 2 diabetes mellitus, it is crucial to choose the right second-line medications. Generally, metformin is the first-line treatment, and the second-line medicine is selected from different anti-diabetic drug groups. This review has discussed glimepiride against teneligliptin as a second-line therapy for type 2 diabetes mellitus. It has been shown that both drugs have an effective role in improving glycaemic levels. Whereas teneligliptin has shown to have more benefits, such as it significantly controls glycaemic parameters in a shorter period with safety, enhances weight loss, and no dose adjustment is required in really impaired diabetes patients. Thus, compared to glimepiride, teneligliptin is a better choice as a second-line drug for type 2 diabetes mellitus after metformin usage, irrespective of the patient's age and gender.

Conflict of interest - The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

REFERENCES

1. Goyal R, Jialal I. Diabetes mellitus type 2.
2. Maruthur NM, Tseng E, Hutffless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. *Annals of internal medicine*. 2016 Jun 7;164(11):740-51.
3. Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, Corliano F, FraGP, Bartoli E, Derosa G. State of the art paper sulfonylureas and their use in clinical practice. *Archives of Medical Science*. 2015 Aug 10;11(4):840-8.
4. Sulfonylurea [Internet]. Sulfonylurea - an overview | ScienceDirect Topics. [cited 2023Mar8].
5. Karmoker JR, Priya RJ, Sarkar S, Islam S. Comparative in vitro equivalence evaluation of some local Gliclazide brands of Bangladesh. *The Pharma Innovation*. 2017 Mar 1;6(3, Part C):152.
6. Talbert RL, Wells B, Posey LM. *Pharmacotherapy: A pathophysiologic approach*. McGraw Hill Professional; 2011 Apr 4.
7. Davidson JK, editor. *Clinical diabetes mellitus: a problem-oriented approach*. Thieme Medical Pub; 1991.
8. Lee YH, Lee BW, Chun SW, Cha BS, Lee HC. Predictive characteristics of patients achieving glycaemic control with insulin after sulfonylurea failure. *International journal of clinical practice*. 2011 Oct;65(10):1076-84.
9. Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non—insulin- department diabetes mellitus. *Archives of internal medicine*. 1997 Apr 28;157(8):836-48.
10. Glimepiride [Internet]. Wikipedia. Wikimedia Foundation; 2022 [cited 2023Feb25]. Available from: [https://en.wikipedia.org/wiki/Glimepiride#:~:text=glimepiride%20does%20not-, Pharmacokinetics,it%20is%20hepatic%20and%20-complete](https://en.wikipedia.org/wiki/Glimepiride#:~:text=glimepiride%20does%20not-,Pharmacokinetics,it%20is%20hepatic%20and%20-complete).
11. Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. *Frontiers in endocrinology*. 2019 Feb 15;10:80.
12. Gallwitz B. Novel therapeutic approaches in diabetes. *Novelties in Diabetes*. 2016;31:43-56.
13. Okhunov A. Influence of a granulocyte-colony-stimulating factor on the cytological picture of the wound in patients with purulent-inflammatory diseases of soft tissues on the background of diabetes mellitus. *Research Square*; 2022. DOI: 10.21203/rs.3.rs-2304237/v1.
14. Okhunov A. O. The role and place of nitroxidergic regulation of the endothelial system in the pathogenesis of acute lung abscess. // *Medical & Clinical Research* 7.12 (2022): P. 1-6.
15. Okhunov A. O., Abdurakhmanov F. M. Ways to achieve positive results of dermaplasty in patients with diabetic foot syndrome. // *British Medical Journal* 3.1 (2023).
16. Okhunov A. O., Boboev Q. Kh., Valijonov A. Principles of diagnosis and treatment of acute purulent-destructive lung diseases. // *World Bulletin of Public Health*, 2022, #7, P. 1-2. Retrieved from <https://scholarexpress.net/index.php/wbph/article/view/526>
17. Okhunov A. O., Bobokulova Sh. A. Differentiated approaches to the diagnosis and treatment of acute lung abscesses in patients who have had COVID-19. // *British Medical Journal*, 2023, # 3.1.
18. Okhunov A. O., Khamdamov Sh. A. Evaluation of the effectiveness of various methods of treatment of acute purulent-destructive lung diseases in patients with diabetes mellitus. // *British Medical Journal*, 2023, # 3.2.
19. Okhunov A. O., Khamdamov Sh. A. A combination of diabetes mellitus and acute purulent-destructive lung diseases solving the problems of diagnosis and treatment. // *World Bulletin of Public Health*, 2023, #19, P. 127-135. Retrieved from <https://scholarexpress.net/index.php/wbph/article/view/2149>
20. Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G, Dauriz M, Dotta F, Formichi C, Frontoni S, Invitti C. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. *Acta diabetologica*. 2019 Jun 1;56:605-17.
21. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. *Expert opinion on pharmacotherapy*. 2013 Oct 1;14(15):2047-58.
22. Scheen AJ. The safety of gliptins: updated data in 2018. *Expert opinion on drug safety*. 2018 Apr 3;17(4):387-405.
23. Ramanathan B. DPP-4 inhibitors in the management of type 2 diabetes mellitus. *Progress in Medicine*. The Association of Physicians of India. 2017:231-7.
24. Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4

inhibitors in type 2 diabetes therapy—focus on alogliptin. Drug design, development and therapy. 2013 Sep 17:989-1001.

25. Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman G, Wagner J. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. *Biopharmaceutics & drug disposition*. 2007 Sep;28(6):315-22.

26. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA [Internet]. *Fda.gov*. [cited 2023 Mar 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/0223501bl.pdf

27. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. *Clinical Pharmacology & Therap*.

28. Okhunov A. O., Korikhonov D. N. Differential diagnosis of necrotizing fasciitis. // *British Medical Journal*, 2023, # 3.1.

29. Okhunov A.O, Bobokulova Sh. A. New approaches to treating lung abscesses as covid19 sequels. // *World Bulletin of Public Health*, 2023, #19, P. 101-107. Retrieved from <https://scholarexpress.net/index.php/wbph/article/view/2281>

30. Okhunov A.O. Endovascular methods for correcting angiopathy of the diabetic foot syndrome in patients after COVID-19 // 16th European Diabetes and Endocrinology Congress – 2022, P.12-15.

31. Okhunov A.O. Endovascular methods for correcting angiopathy of the diabetic foot syndrome in patients after COVID-19. // 16th European Diabetes and Endocrinology Congress. – 2022. – P.12-15.

32. Okhunov A.O. Postoperative complications issues after the application of various abdominoplasty techniques. // 4-international conference of the European Academy of Science. – 2019. – P.23-24.

33. Okhunov A.O. Prediction and prevention of sepsis in patients with necrotizing fasciitis on the background of diabetes mellitus // 42-Annual Meeting of the Surgical Infection Society, Westlake Village, CA, 2023, April 11-14, P.39.

34. Okhunov A.O. Prediction and prevention of sepsis in patients with necrotizing fasciitis on the background of diabetes mellitus. // Conference «42-Annual Meeting of the Surgical Infection Society, Westlake Village, CA April 11-14, 2023» - P.39.

35. Okhunov A.O., Abdurakhmanov F.A. Prolonged intraarterial catheter therapy for diabetic gangrene of the lower limb. // Conference «42-Annual Meeting of the Surgical Infection Society, Westlake Village, CA April 11-14, 2023» - P.38.

36. Okhunov A.O., Abdurakhmanov F.M. Prolonged intraarterial catheter therapy for diabetic gangrene of the lower limb // 42-Annual Meeting of the Surgical Infection Society, Westlake Village, CA April 11-14, 2023 – P.38

37. Okhunov A.O., Boboev K.Kh. Etiological factors leading to purulent mediastinitis. // *World Bulletin of Public Health*, 2023, #18, P. 118-125.

38. Okhunov A.O., Boboev K.Kh. Etiology and pathogenesis of primary purulent mediastinitis. // *British Medical Journal*, 2023, #3.1.

39. Oxunov A.O., Babadjanov B.D., Pulatov U.I. Sepsis. - Patent RUz DGU 04057 ot 13.10.2016 g. [in Russian].

40. Oxunov A.O., Pulatov U.I., Oxunova D.A. Morfologicheskaya xarakteristika techeniya ranevogo protsessa pri gnoyno-vospalitel'nix zabolevaniyax myagkix tkaney na fone saxarnogo diabeta. // *Vestnik nauki i obrazovaniya*. – 2018. - №9 (45). – S.98-104. [in Russian].

41. Principles of Diagnosis and Treatment of Acute purulent-destructive lung diseases. / A.O. Okhunov, K.X. Boboev, A.F. Valijonov, et al. // *World Bulletin of Public Health*. – 2022. – Vol.7. – P.1-2.

42. Puti uluchsheniya rezultatov lecheniya bo'lynyx s gnoyno-vospalitel'nymi porajeniyami myagkix tkaney na fone saxarnogo diabeta. / A.O. Oxunov, U.I. Pulatov, B.D. Babadjanov, et al. // *TAJRIR JAYATI*. - 2012. - S.82. [in Russian].

43. Sayfullaeva S.A. Aktivnost monooksigenaznoy i nitregicheskoy sistem v mikrosomax pecheni pri deystvii na organizm induktorov i ingibitorov lekarstvennogo metabolizma // *Vrach-aspirant*. - 2013. - Tom 59. - №4. - S.73-78. [in Russian].

44. Sayfullaeva S.A. Metabolicheskaya aktivnost mikrosom slizistoy obolochki kulti jeludka posle rezektsii porajennogo yazvennim protsessom uchastka gastroduodenalnoy zone // *Vrach-aspirant* - 2010. - Tom. 39. - №2.1. - S.131-140. [in Russian].

How to Cite: Saara A., Gopal K., Karthick S., et al. A review on glimepiride vs teneligliptin as a second-line drug for the treatment of type 2 diabetes mellitus // *Journal of Educational & Scientific Medicine*, 2023. Vol. 2, Issue 3, P. 73-79

45. Shadmanov A.K. A new method of treating pneumonia complicated by an abscess in patients after Covid-19. // *Journal of Education and Scientific Medicine*. – 2023. – Vol.1. - #2. – P.2-9.

46. Shadmanov A.K. Features of the Educational Program in Foreign Universities: The Example of the Medical College of the University of Central

Florida // *Journal of Education and Scientific Medicine*. – 2023. – Vol.2. - #2. – P.2-9.

47. The microbiological environment of wounds and skin in patients with purulent-inflammatory diseases of soft tissues. / W.S. Jonson, A.O. Okhunov, S.S. Atakov, et al. // *Journal of Education and Scientific Medicine*. – 2023. – Vol.2. - #2. – P.72-81.